{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104983",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104983",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for tacrolimus and CYP3A5",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA451578",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA451578",
    "name" : "tacrolimus"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA131",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA131",
    "symbol" : "CYP3A5",
    "name" : "cytochrome P450, family 3, subfamily A, polypeptide 5"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>There is evidence to support an interaction between tacrolimus and CYP3A5, however, there are no dosing recommendations at this time.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for tacrolimus based on CYP3A5 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They found evidence to support an interaction between tacrolimus and CYP3A5.  However, they make no dosing recommendations at this time, due to fact that \"in Dutch transplantation hospitals the tacrolimus dose is titrated in response to therapeutic drug monitoring.\"</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Genotype </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> CYP3A5 *1/*1 </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x109/l; leucopenia &gt; 3.0x109/l; thrombocytopenia  &gt; 75x109/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test. </td></tr><tr><td> CYP3A5 *1/*3 </td><td> None </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (&gt; 168 hr), permanent symptom or invalidating injury e.g. failure of prophylaxis of atrial fibrillation; venous thromboembolism; decreased effect of clopidogrel on inhibition of platelet aggregation; ADE resulting from increased bioavailability of phenytoin; INR &gt; 6.0; neutropenia 0.5-1.0x109/l; leucopenia 1.0-2.0x109/l; thrombocytopenia 25-50x109/l; severe diarrhea. </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li></ul>"
}